DLL3-Targeted ADC ZL-1310 Shows Early Promise in Neuroendocrine Carcinomas

/in , , /by

Early-phase data from the ZL-1310-002 trial introduce a potentially important new therapeutic option for patients with advanced neuroendocrine carcinomas (NECs), a group of aggressive malignancies with very limited treatment options after platinum-based chemotherapy. Among these, neuroendocrine prostate cancer (NEPC) represents one of the most clinically challenging subtypes, characterized by rapid progression, resistance to androgen receptor–targeted […]

Read more

Early Results for ACE‑106 (ACE‑86225106): A Selective PARP1 Inhibitor for HRR‑Mutant Cancers

/in , , /by

ACE‑106 (ACE‑86225106) is a highly selective PARP1 inhibitor designed to improve the therapeutic index compared with first‑generation pan‑PARP inhibitors, which broadly inhibit both PARP1 and PARP2 while causing substantial hematologic toxicity. The updated first‑in‑human data from the open‑label, dose‑escalation study show that ACE‑106 is well tolerated, with no dose‑limiting toxicities, no grade 4–5 treatment‑related adverse […]

Read more

Phase 1 225Ac-J591 Trial: Strong Activity in Advanced Prostate Cancer, with Improved Outcomes Using a Fractionated Dosing Approach

/in , /by

225Ac-J591 (Actinium-225 rosopatamab tetraxetan) uses a radioactive particle linked to an antibody that targets PSMA, a protein found on prostate cancer cells, and it is being studied in a phase 1 clinical trial. Unlike more commonly used PSMA treatments that rely on small molecules, this approach uses an antibody, which behaves differently in the body. […]

Read more

Astatine-211 PSMA-5: Scalable Alpha Therapy for Refractory Prostate Cancer

/in , , /by

211AtPSMA-5 emerges as a promising targeted alpha therapy for metastatic castration-resistant prostate cancer, particularly in patients who have exhausted standard treatments like androgen receptor pathway inhibitors, docetaxel, and cabazitaxel. This approach leverages astatine-211, a cyclotron-produced alpha emitter generated by bombarding abundant bismuth targets with alpha beams. The compound’s design mirrors established PSMA ligands such as […]

Read more

EXS74539: A New LSD1 Inhibitor for Hard-to-Treat Solid Tumors, Including Prostate Cancer

/in , , /by

EXS74539, also called REC-4539, is an experimental cancer drug designed to block LSD1, a protein that helps some cancer cells grow and survive even when standard treatments fail. It is being tested in a phase 1 trial on people with selected solid tumors, including small-cell lung cancer, prostate cancer, ovarian cancer and others. This early-stage […]

Read more

TSL2109: A Novel Dual-Target Cancer Drug for Resistant Prostate Cancer

/in , , /by

TSL2109 is an experimental oral cancer drug being studied in people with advanced solid tumors, especially metastatic castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, or APMR, God save us!) and advanced hormone receptor–positive, HER2-negative breast cancer. It is designed to hit two important targets at once, CDK4/6 and DYRK2, which may help […]

Read more

UPDATE: Phase 1 Trial for RAD 402 Dosed the First Patient

/in , , /by

Following our previous article, we are pleased to report that patient dosing has commenced in this trial. First patient has been dosed in this Phase 1 dose-escalation trial evaluating RAD 402, an anti-KLK3 (PSA) monoclonal antibody radiolabeled with Terbium-161 (Tb-161), in patients with advanced prostate cancer previously treated with standard therapies. Following our past article, […]

Read more

Phase 1 Trial: Dual-Target ADC IDE034 Targets B7-H3/PTK7 in Prostate Cancer

/in , , /by

A promising new bispecific antibody-drug conjugate (ADC) known as IDE034 is entering early clinical testing in patients with advanced solid tumors, including prostate cancer, marking a potential step forward in precision oncology. This Phase 1a/1b trial, which began dosing its first patient in February 2026, targets tumors expressing both B7-H3 and PTK7, two surface proteins […]

Read more

New Xaluritamig (AMG 509) Monotherapy Phase 1 Trial for mCRPC

/in , , /by

Xaluritamig (AMG 509) represents a promising new immunotherapy option for men with metastatic castration-resistant prostate cancer, or mCRPC, through this  new Phase 1 trial. The study aims to evaluate the safety profile of xaluritamig administered as monotherapy (plus ADT, as usual) at a specific proposed regimen in adult male participants whose cancer has progressed despite […]

Read more

Soon to Be Phase 1 Trial: FX‑111, A Selective ARon Degrader with the Potential to Rethink Androgen Deprivation in Prostate Cancer

/in , , /by

A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current […]

Read more